Keywords: GlaxoSmithKline, Cervaris, Tyverb, Meck & Co, Gardasil, NICE, UK, USA
UK’s NICE won’t fund GSK’s breast cancer drug Tyverb; USA’s CDC backs Cervarix and Merck & Co’s Gardasil for boys
Article | 22 October 2009
Vaccines and breast cancer drug final appraisals were in focus yesterday for UK drug giant GlaxoSmithKline and US major Merck & Co with decisions on the availability of products for the two companies in both the UK and USA being issued.
The UK’s National Institute for health and Clinical Excellence (NICE) issued its final appraisal determination advising against National Health Service funding for GSK’s Tyverb (lapatinib), a treatment for an aggressive form of advanced breast cancer (ErbB2-positive). Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
